Hear directly from leading doctors and health care professionals as they share real-world insights on treatment with PLUVICTO. Discover practical knowledge, clinical perspectives, and key takeaways to help you better understand its impact and to inform your patient care decisions.
Learn what medical experts have to say about PLUVICTO in mAPMN/S PC (mHSPC)1
Multidisciplinary Perspectives on PLUVICTO Across the Metastatic APMN/S and APMR Prostate Cancer (mHSPC and mCRPC) Continuum
Radiation oncologist Travis Mendel, MD, is joined by medical oncologist Jahan Aghalar, MD, and urologist Neal Shore, MD, to discuss PLUVICTO efficacy and safety in mAPMN/S (mHSPC) and mAPMR prostate cancer (mCRPC), including insights from PSMAddition.
Identifying the Right Patients for Early PSMA‑Targeted Therapy
Medical oncologist Jahan Aghalar, MD, shares clinical perspectives on earlier use of PLUVICTO in PSMA‑positive mAPMN/S prostate cancer (mHSPC), using a patient case to highlight patient selection, early clinical decision‑making, and shared discussions.
Operationalizing PLUVICTO in Metastatic APMN/S Prostate Cancer (mHSPC): A Medical Oncologist’s Perspective
Medical oncologist Jahan Aghalar, MD, discusses clinical considerations for operationalizing PLUVICTO in PSMA‑positive mAPMN/S prostate cancer (mHSPC), including multidisciplinary coordination, workflow, and referral pathways.
Why Urologists Need PLUVICTO in Their Metastatic APMN/S Prostate Cancer (mHSPC) Treatment Armamentarium, and How to Get Started
Urologist Neal Shore, MD, shares a clinical perspective on initiating PLUVICTO for appropriate patients with PSMA‑positive mAPMN/S prostate cancer (mHSPC), including considerations for earlier intensification and integration into urology practices.
Identifying Patients With Metastatic APMN/S Prostate Cancer (mHSPC) for PLUVICTO in Your Urology Practice
Urologist Neal Shore, MD, discusses identifying patients with PSMA‑positive mAPMN/S prostate cancer (mHSPC) who may be appropriate for PLUVICTO, including early identification and multidisciplinary coordination in practice.
Learn what medical experts have to say about PLUVICTO in mAPMR PC (mCRPC) after only 1 ARPI1
Planning Ahead for PLUVICTO for Patients With Metastatic APMR Prostate Cancer (mCRPC)
Urologist Jose De La Cerda, MD, provides insights about the importance of aggressive treatment for patients with advanced prostate cancer as well as considerations about planning for PLUVICTO.
Identifying Progression in Patients With Metastatic APMR Prostate Cancer (mCRPC) to Plan Ahead for PLUVICTO
Urologist Scott Sellinger, MD, provides insights about the importance of progression and guideline-aligned therapy options in advanced prostate cancer after an ARPI, including the importance of presenting PLUVICTO as a therapy option at first eligibility.
Optimizing Treatment in Metastatic APMR Prostate Cancer (mCRPC) Beyond ARPI
Medical oncologist Bradley Somer, MD, shares insights on optimizing treatment in advanced prostate cancer beyond ARPI therapy, highlighting the need for continued education on logistics and key stakeholders to build HCP comfort with PLUVICTO.
Acting Early for Patients With Metastatic APMR Prostate Cancer (mCRPC)
Learn from Aaron Berger, MD, about the need for aggressive therapy when treating mAPMR prostate cancer (also known as mCRPC) and PLUVICTO as an option.
Choosing the Optimal Therapy Early for Patients With Metastatic APMR Prostate Cancer (mCRPC)
MEs sharing first‑hand referral experiences and the key moments that led them to choose PLUVICTO, reinforcing triggers for mAPMR prostate cancer (mCRPC) referral and easing common HCP concerns.
Providing PLUVICTO at the Earliest Eligible Opportunity for Patients With Metastatic APMR Prostate Cancer (mCRPC)
MEs sharing first‑hand referral experiences and the key moments that led them to choose PLUVICTO, reinforcing triggers for mAPMR prostate cancer (mCRPC) referral and easing common HCP concerns.
Care Team Perspectives for a Patient With Metastatic APMN/S Prostate Cancer (mHSPC) Who Received an ARPI and Recently Progressed to Metastatic APMR Prostate Cancer (mCRPC)
Nuclear medicine physician Dr Phillip Koo, medical oncologist Dr Scott Tagawa, and urologist Dr Jason Hafron, review a case of a patient previously treated with an ARPI for mAPMN/S prostate cancer (mHSPC) who progressed to mAPMR prostate cancer (mCRPC).
Medical Expert Perspectives on a Patient With Metastatic APMR Prostate Cancer (mCRPC) After Progression on an ARPI
Watch as nuclear medicine physician Dr Phillip J. Koo, medical oncologist Dr Scott T. Tagawa, and urologist Dr Jason M. Hafron discuss options for a patient with mAPMR prostate cancer (mCRPC) who experienced progression after an ARPI.
Considerations for Providing PLUVICTO in a Urology Setting: A Conversation With Dr Finkelstein and Dr Pieczonka
Steven Finkelstein, MD and Christopher Pieczonka, MD, discuss considerations and their experience for ordering and providing PLUVICTO to patients with PSMA+ mAPMR prostate cancer (mCRPC), prior to chemotherapy.
Earlier Use of PLUVICTO Prior to Chemotherapy: An Expert Dialogue
Watch Steven Finkelstein, MD, and Christopher Pieczonka, MD, talk about treating the first US patient to receive PLUVICTO after its approval for use prior to chemotherapy, along with other key considerations when discussing PLUVICTO with patients.
Expert Panel Perspectives on the Efficacy and Safety of PLUVICTO in PSMAfore
Watch Ulka Vaishampayan, MD, together with Chad Reichard, MD, and Gregg Franklin, MD, PhD, share insights on the PSMAfore trial, presenting the efficacy and safety data for PLUVICTO in patients with PSMA+ mAPMR prostate cancer (mCRPC).
Importance of Early Action in Care for Patients With Metastatic APMR Prostate Cancer (mCRPC)
Ulka Vaishampayan, MD, Chad Reichard, MD, and Gregg Franklin, MD, PhD, discuss early, effective treatment for mAPMR prostate cancer (mCRPC), PSMA-PET in patient selection, and how targeted radioligand therapies like PLUVICTO work.
Best Practices in Providing Treatment as a Multidisciplinary Team
Ulka Vaishampayan, MD, with Chad Reichard, MD, and Gregg Franklin, MD, PhD, share best practices in patient care and key PLUVICTO administration considerations, highlighting a multidisciplinary approach for patients with mAPMR prostate cancer (mCRPC).
APMN/S, androgen pathway modulation-naive or -sensitive; APMR, androgen pathway modulation-resistant; ARPI, androgen receptor pathway inhibitor; HCP, health care professional; mAPMN/S PC, metastatic androgen pathway modulation-naive or -sensitive prostate cancer; mAPMR PC, metastatic androgen pathway modulation-resistant prostate cancer; mCRPC, metastatic castration-resistant prostate cancer; mCSPC, metastatic castration-sensitive prostate cancer; mHSPC, metastatic hormone-sensitive prostate cancer; PET, positron emission tomography; PSMA, prostate-specific membrane antigen; PSMA+, PSMA positive.
Discover medical expert presentations about PLUVICTO from live events
Advancing PLUVICTO Therapy for the Right Patients
Glen Gejerman, MD, MBA, reviews what PLUVICTO therapy is at a live event, summarizing PLUVICTO data, presenting a hypothetical case of a patient with PSMA+ mAPMR prostate cancer (mCRPC), and highlighting what types of patients are eligible for PLUVICTO.
How to Communicate PLUVICTO Radiation Safety With Your Patients
Radiation oncologist Glen Gejerman, MD, MBA, presenting at a live event, provides insights and best practices for communicating radiation safety with patients receiving PLUVICTO.
Learn what medical experts have to say about PLUVICTO in mCRPC after ARPI and chemo1
VISION Efficacy and Safety
Join Gordon Brown, DO, Mark Fleming, MD, Glen Gejerman, MD, and Christina Fareri, LPN, as they review the results of the VISION trial.
Watch patients, care partners, and doctors discuss treatment with PLUVICTO
See patients' perspectives of PLUVICTO in the videos below.
Talking to Your Care Team After Progression
Watch patients, care partners, and doctors discuss how to navigate treatment with PLUVICTO in this Flip the Script video.
Discover the Role PSMA Plays
Watch patients, care partners, and doctors discuss how to navigate treatment with PLUVICTO in this Flip the Script video.
How Doctors Think About What's Next
Watch patients, care partners, and doctors discuss how to navigate treatment with PLUVICTO in this Flip the Script video.
What It's Like Taking PLUVICTO
Watch patients, care partners, and doctors discuss how to navigate treatment with PLUVICTO in this Flip the Script video.
For Patients and Care Partners Considering Treatment
Join health care professionals for a cup of coffee as they discuss considerations for potential and current PLUVICTO patients in this Diner Discussions video.
For Those Already Prescribed PLUVICTO
Join health care professionals for a cup of coffee as they discuss considerations for potential and current PLUVICTO patients in this Diner Discussions video.
Read the latest clinical perspectives on PLUVICTO
The Bullseye: The PSMAfore Study in Review
Jason Hafron, MD, Phillip Koo, MD, and Scott Tagawa, MD, share insights on the PSMAfore study in the second installment of The Bullseye.
The Bullseye: PLUVICTO in Practice
In the third installment of The Bullseye, Christopher Pieczonka, MD, and Steven Finkelstein, MD, describe their experience working with Novartis and providing PLUVICTO to patients with PSMA+ mAPMR prostate cancer (mCRPC), prior to chemotherapy.
The Bullseye: PSMAddition Edition
Coming soon